

Vemlidy® Registration In The Developing World

Approved

1.	Argentina	December 2017
2.	Chile	March 2019
3.	Costa Rica	December 2018
4.	Dominican Republic	October 2018
5.	El Salvador	May 2018
6.	Guatemala	June 2018
7.	India	October 2017
8.	Indonesia	January 2019
9.	Kazakhstan	May 2019
10.	Kyrgyzstan	December 2018

11.	Mexico	December 2017
12.	Mongolia	June 2017
13.	Mozambique	December 2018
14.	Nigeria	January 2019
15.	Panama	September 2018
16.	Philippines	March 2019
17.	Thailand	August 2018
18.	Uganda	April 2018
19.	Uzbekistan	December 2017

Filed

1.	Bolivia	June 2017
2.	Brazil	December 2017
3.	Colombia	September 2017
4.	Ecuador	February 2019
5.	Ethiopia	January 2018
6.	Ghana	September 2017
7.	Kenya	March 2018
8.	Madagascar	March 2019
9.	Myanmar	October 2018
10.	Pakistan	July 2017

11.	Paraguay	July 2017
12.	Peru	July 2017
13.	Rwanda	October 2017
14.	South Africa	October 2017
15.	Tanzania	October 2017
16.	Uruguay	July 2017
17.	Vietnam	January 2018
18.	Zambia	September 2017

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Note

There can be no guarantee that marketing approval for Vemlidy® for the treatment of hepatitis B will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.